{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:47:08Z","timestamp":1773434828797,"version":"3.50.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Poorly differentiated endometrioid adenocarcinoma and serous adenocarcinoma represent an aggressive subtype of endometrial cancer (EC). Programmed death-ligand-1 (PD-L1) was known to exhibit a tumor cell-intrinsic function in mediating immune-independent tumor progression. However, the functional relevance of tumor cell-intrinsic PD-L1 expression in aggressive EC cells and the mechanisms regulating its expression remain unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PD-L1 expression in 65 EC tissues and 18 normal endometrium samples was analyzed using immunohistochemical staining. The effects of PD-L1 on aggressive EC cell growth, migration and invasion were investigated by cell functional assays. Luciferase reporter assays were used to reveal the microRNA-216a (miR-216a)-dependent mechanism modulating the expression of PD-L1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Positive PD-L1 expression was identified in 84% of benign cases but only in 12% of the EC samples, and the staining levels of PD-L1 in EC tissues were significantly lower than those in the normal tissues. Higher PD-L1 expression predicts favorable survival in EC. Ectopic expression of PD-L1 in aggressive EC cells results in decreased cell proliferation and the loss of mesenchymal phenotypes. Mechanistically, PD-L1 exerts the anti-tumor effects by downregulating MCL-1 expression. We found that PD-L1 levels in aggressive EC cells are regulated by miR-216a, which directly targets <jats:italic>PD-L1<\/jats:italic>. We further identified a mechanism whereby the long non-coding RNA MEG3 represses the expression of miR-216a, thereby leading to increased PD-L1 expression and significant inhibition of cell migration and invasion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results reveal an unappreciated tumor cell-intrinsic role for PD-L1 as a tumor suppressor in aggressive EC cells, and identify MEG3 and miR-216a as upstream regulators of PD-L1.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcell.2020.598205","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T04:18:53Z","timestamp":1607487533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3"],"prefix":"10.3389","volume":"8","author":[{"given":"Daozhi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ihira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemichi","family":"Watari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses.","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1159\/000480000","article-title":"PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer.","volume":"42","author":"Chen","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.3892\/etm.2018.5881","article-title":"miR-216a-5p acts as an oncogene in renal cell carcinoma.","volume":"15","author":"Chen","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma.","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.19.00151","article-title":"Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers.","volume":"37","author":"Clarke","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1002\/jcp.26786","article-title":"Mcl-1 targeting could be an intriguing perspective to cure cancer.","volume":"233","author":"De Blasio","year":"2018","journal-title":"J. Cell Physiol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw160","article-title":"FirebrowseR: an R client to the broad institute\u2019s firehose pipeline.","volume":"2017","author":"Deng","year":"2017","journal-title":"Database (Oxford)."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-015-0014-8","article-title":"Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer.","volume":"8","author":"D\u00edez-Villanueva","year":"2015","journal-title":"Epigenet. Chrom."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-99","article-title":"MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.","volume":"10","author":"Dong","year":"2011","journal-title":"Mol. Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0231-0","article-title":"The impact of microRNA-mediated PI3K\/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.","volume":"12","author":"Dong","year":"2014","journal-title":"J. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1038\/s41388-018-0347-4","article-title":"Control of PD-L1 expression by miR-140\/142\/340\/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.","volume":"37","author":"Dong","year":"","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00471","article-title":"Long non-coding RNA NEAT1: a novel target for diagnosis and therapy in human tumors.","volume":"9","author":"Dong","year":"","journal-title":"Front. Genet."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00386","article-title":"Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion.","volume":"8","author":"Dong","year":"","journal-title":"Front. Oncol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1306-9","article-title":"Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.","volume":"38","author":"Dong","year":"","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020234","article-title":"Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: advances and challenges.","volume":"11","author":"Dong","year":"","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","article-title":"Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.","volume":"49","author":"Droeser","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ygyno.2020.01.020","article-title":"High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.","volume":"157","author":"Engerud","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-016-0292-2","article-title":"Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040.","author":"Gaber","year":"2016","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","article-title":"PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity.","volume":"20","author":"Gato-Ca\u00f1as","year":"2017","journal-title":"Cell Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression.","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_280503","article-title":"Review of immune checkpoint blockade therapy in endometrial cancer.","volume":"40","author":"Green","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/sigtrans.2016.30","article-title":"Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.","volume":"1","author":"Gupta","year":"2016","journal-title":"Signal. Transduct Target Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"73282","DOI":"10.18632\/oncotarget.19931","article-title":"Potential applications of MEG3 in cancer diagnosis and prognosis.","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/modpathol.2017.111","article-title":"Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.","volume":"31","author":"Keller","year":"2018","journal-title":"Mod. Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mco.2012.28","article-title":"Epigenetic control of epithelial-mesenchymal-transition in human cancer.","volume":"1","author":"Kiesslich","year":"2013","journal-title":"Mol. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors.","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.18632\/oncotarget.2157","article-title":"MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.","volume":"5","author":"Konno","year":"2014","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/S0002-9440(10)63583-3","article-title":"Successful immortalization of endometrial glandular cells with normal structural and functional characteristics.","volume":"163","author":"Kyo","year":"2003","journal-title":"Am. J. Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","article-title":"starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.","volume":"42","author":"Li","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/IGC.0000000000001120","article-title":"Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency.","volume":"28","author":"Li","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.","volume":"1","author":"Lipson","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/OTT.S114318","article-title":"MicroRNA-216a promotes the metastasis and epithelial-mesenchymal transition of ovarian cancer by suppressing the PTEN\/AKT pathway.","volume":"10","author":"Liu","year":"2017","journal-title":"Onco Targets Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3892\/etm.2015.2714","article-title":"Expression of immune checkpoint molecules in endometrial carcinoma.","volume":"10","author":"Liu","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00189","article-title":"L1 expression is associated with VEGFA and LADC patients\u2019 survival.","volume":"9","author":"Liu","year":"2019","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01073","article-title":"The controversial role of PD-1 and its ligands in gynecological malignancies.","volume":"9","author":"Marinelli","year":"2019","journal-title":"Front Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3892\/ol.2016.4744","article-title":"Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.","volume":"12","author":"Mo","year":"2016","journal-title":"Oncol. Lett."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27521-y","article-title":"Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.","volume":"8","author":"Nagy","year":"2018","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application.","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baz148","article-title":"miR-TV: an interactive microRNA Target Viewer for microRNA and target gene expression interrogation for human cancer studies.","volume":"2020","author":"Pan","year":"2020","journal-title":"Database (Oxford)."},{"key":"B43","doi-asserted-by":"publisher","first-page":"D77","DOI":"10.1093\/nar\/gkz947","article-title":"Expression Atlas update: from tissues to single cells.","volume":"48","author":"Papatheodorou","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"D231","DOI":"10.1093\/nar\/gkv1270","article-title":"DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts.","volume":"44","author":"Paraskevopoulou","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy.","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","article-title":"PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation.","volume":"1864","author":"Qiu","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/cas.12406","article-title":"Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma.","volume":"105","author":"Tamai","year":"2014","journal-title":"Cancer Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/1878-0261.12093","article-title":"New insights into the role of EMT in tumor immune escape. Version 2.","volume":"11","author":"Terry","year":"2017","journal-title":"Mol. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12079-017-0441-3","article-title":"Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer.","volume":"12","author":"Tripathi","year":"2018","journal-title":"J. Cell Commun. Signal."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome.","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms.","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00639-2","article-title":"LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration.","volume":"13","author":"Wang","year":"2020","journal-title":"J. Ovarian Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","article-title":"Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/hep.26369","article-title":"MicroRNA-216a\/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.","volume":"58","author":"Xia","year":"2013","journal-title":"Hepatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment.","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030632","article-title":"MicroRNA-361-mediated inhibition of HSP90 expression and EMT in cervical cancer is counteracted by oncogenic lncRNA NEAT1.","volume":"9","author":"Xu","year":"2020","journal-title":"Cells"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e32","article-title":"Clinical statistics of gynecologic cancers in Japan.","volume":"28","author":"Yamagami","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.","volume":"9","author":"Yamashita","year":"2017","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41251-9","article-title":"RNAi-mediated PD-L1 inhibition for pancreatic cancer immunotherapy.","volume":"9","author":"Yoo","year":"2019","journal-title":"Sci. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1002\/ijc.30656","article-title":"Down-regulation of KIAA1199\/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.","volume":"140","author":"Zhang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6545-9","article-title":"PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2020.598205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T04:18:55Z","timestamp":1607487535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2020.598205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":63,"alternative-id":["10.3389\/fcell.2020.598205"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.598205","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"article-number":"598205"}}